1. Regarding the evidence-based use of micronized progesterone
- Author
-
A. D. Makatsariya, G. C. Di Renzo, G. Rizzo, V. O. Bitsadze, J. Kh. Khizroeva, D. V. Blinov, E. I. Vovk, I. E. Govorov, D. L. Guryev, G. B. Dikke, M. S. Zainulina, N. S. Zakharova, V. V. Kovalev, E. V. Komlichenko, V. A. Kramarskiy, A. B. Loginov, L. I. Maltseva, V. B. Nemirovskiy, D. A. Ponomarev, E. B. Rudakova, N. V. Samburova, O. F. Serova, F. K. Tetelyutina, M. V. Tretyakova, J. Yu. Ungiadze, and V. I. Tsibizova
- Subjects
Embryology ,Evidence-based practice ,Coronavirus disease 2019 (COVID-19) ,progesterone ,didrogesterone ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,Pandemic ,Medicine ,030212 general & internal medicine ,Mass media ,Medical education ,030219 obstetrics & reproductive medicine ,habitual miscarriage ,Health professionals ,business.industry ,gestagenes ,Obstetrics and Gynecology ,Gynecology and obstetrics ,Micronized progesterone ,medicine.disease ,Reproductive Medicine ,Settore MED/40 ,evidence base ,RG1-991 ,Objective information ,business - Abstract
An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcareworkers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by us, displays signs of prejudiced data manipulation and may disorient practitioners. In this Letter we provide objective information on accumulated data regarding gestagenes efficacy and safety. We invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.
- Published
- 2020